ASO Author Reflections: Biopsy Guided Pathological Response Assessment in Breast Cancer is Insufficient: Additional Pathology Findings of the MICRA Trial-Reference-Cited by-同舟云学术

ASO Author Reflections: Biopsy Guided Pathological Response Assessment in Breast Cancer is Insufficient: Additional Pathology Findings of the MICRA Trial

Published:2023-05-18 Issue:8 Volume:30 Page:4690-4692
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

van Hemert Annemiek K. E.^ORCID,van Duijnhoven Frederieke H.,Vrancken-Peeters Marie-Jeanne T. F. D.

Funder

Dutch Innovation Fund Health Insurers

KWF Kankerbestrijding

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

https://link.springer.com/content/pdf/10.1245/s10434-023-13546-9.pdf

Reference20 articles.

1. Murphy BL, Day CN, Hoskin TL, Habermann EB, Boughey JC. Neoadjuvant chemotherapy use in breast cancer is greatest in excellent responders: triple-negative and HER2+ subtypes. Ann Surg Oncol. 2018;25(8):2241–8. https://doi.org/10.1245/s10434-018-6531-5.

2. van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentje VO, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(12):1630–40. https://doi.org/10.1016/S1470-2045(18)30570-9.

3. von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15(7):747–56. https://doi.org/10.1016/S1470-2045(14)70160-3.

4. Tasoulis MK, Lee HB, Yang W, Pope R, Krishnamurthy S, Kim SY, et al. Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict residual cancer. JAMA Surg. 2020;155(12):e204103. https://doi.org/10.1001/jamasurg.2020.4103.

5. van Loevezijn AA, van der Noordaa MEM, van Werkhoven ED, Loo CE, Winter-Warnars GAO, Wiersma T, et al. Minimally invasive complete response assessment of the breast after neoadjuvant systemic therapy for early breast cancer (micra trial): interim analysis of a multicenter observational cohort study. Ann Surg Oncol. 2021;28(6):3243–53. https://doi.org/10.1245/s10434-020-09273-0.